PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET
Company Participants
Jane Hanlon - Associate Director, Investor Relations
Matthew Klein - Chief Executive Officer
Eric Pauwels - Chief Business Officer
Pierre Gravier - Chief Financial Officer
Conference Call Participants
Rick Bienkowski - Cantor Fitzgerald
Eric Joseph - JPMorgan
Kelly Shi - Jefferies
Michael Riad - Morgan Stanley
Brian Abraham - RBC Capital Markets
Ellie Merle - UBS
Joel Beatty - Baird
Sami Corwin - William Blair
Peyton Bohnsack - TD Cowen
Paul Choi - Goldman Sachs
Gena Wang - Barclays
Danielle Brill - Raymond James
Joseph Schwartz - Leerink Partners
Operator
Welcome to the PTC Third Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Again please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Jane Hanlon, Associate Director of Investor Relations. Please go ahead.
Jane Hanlon
Good afternoon and thank you for joining us today to discuss PTC Therapeutics' third quarter 2024 corporate update and financial results. I am joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier.
Today's call will include forward-looking statements based on our current expectations. Please take a moment to review the slide posted on our investor relations website in conjunction with the call, which contains information about our forward-looking statements.
Our actual results could materially differ from these forward-looking statements, as such statements are subject to risks that can materially and adversely affect our business and the results of operations.
For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the Securities and Exchange Commission as well as the company's other SEC filings.
We will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and a reconciliation of GAAP to non-GAAP are available in today's earnings release.
With that let me pass the call over to our CEO, Matthew Klein. Matt?
Matthew Klein
Thank you all for joining the call today. I'm happy to share the results of another quarter of outstanding commercial performance and pipeline execution. In the third quarter, we achieved total revenue of $197 million, including $124 million from the DMD franchise.